Citations

Clear

154 citation(s) found for "Levin, G".

The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications
Ramnarine, Varune Rohan , Alshalalfa, Mohammed , Mo, Fan , Nabavi, Noushin , Erho, Nicholas , Takhar, Mandeep, Shukin, Robert, Brahmbhatt, Sonal, Gawronski, Alexander , Kobelev, Maxim , Nouri, Mannan , Lin, Dong , Tsai, Harrison , Karnes, R., Rubin, Mark A. , Zoubeidi, Amina , Gleave, Martin , Sahinalp, Cenk, Wyatt, Alexander W. , Beltran, Himisha , Wang, Yuzhuo , Collins, Colin C. , Karnes, R Jefferey, Lotan, Tamara Levin , Karnes, R. Jeffrey, Şahinalp, S. Cenk , Volik, Stanislav V. , Davicioni, Elai , Rubin, Mark A

Mayo Clinic

GigaScience | May 10, 2018 | Volume: 7 | Issue: 6 | Pages: No page available

10.1093/gigascience/giy050 | PMID 29757368 Get It

Abstract Background Treatment-induced neuroendocrine prostate cancer (tNEPC) is an aggressive variant of late-stage metastatic castrate-resistant prostate cancer that commonly arises through neuroendocrine transdifferentiation (NEtD). Treatment options are limited, ineffective, and, for most patients, result in death in less than a year. We previously developed a first-in-field patient-derived xenograft (PDX) model of NEtD. Longitudinal deep transcriptome profiling of this model enabled monitoring of dynamic transcriptional changes during NEtD and in the context of androgen deprivation. Long non-coding RNA (lncRNA) are implicated in cancer where they can control gene regulation. Until now, the expression of lncRNAs during NEtD and their clinical associations were unexplored. Results We implemented a next-generation sequence analysis pipeline that can detect transcripts at low expression levels and built a genome-wide catalogue (n = 37,749) of lncRNAs. We applied this pipeline to 927 clinical samples and our high-fidelity NEtD model LTL331 and identified 821 lncRNAs in NEPC. Among these are 122 lncRNAs that robustly distinguish NEPC from prostate adenocarcinoma (AD) patient tumours. The highest expressed lncRNAs within this signature are H19, LINC00617, and SSTR5-AS1. Another 742 are associated with the NEtD process and fall into four distinct patterns of expression (NEtD lncRNA Class I, II, III, and IV) in our PDX model and clinical samples. Each class has significant (z-scores >2) and unique enrichment for transcription factor binding site (TFBS) motifs in their sequences. Enriched TFBS include (1) TP53 and BRN1 in Class I, (2) ELF5, SPIC, and HOXD1 in Class II, (3) SPDEF in Class III, (4) HSF1 and FOXA1 in Class IV, and (5) TWIST1 when merging Class III with IV. Common TFBS in all NEtD lncRNA were also identified and include E2F, REST, PAX5, PAX9, and STAF. Interrogation of the top deregulated candidates (n = 100) in radical prostatectomy adenocarcinoma samples with long-term follow-up (median 18 years) revealed significant clinicopathological associations. Specifically, we identified 25 that are associated with rapid metastasis following androgen deprivation therapy (ADT). Two of these lncRNAs (SSTR5-AS1 and LINC00514) stratified patients undergoing ADT based on patient outcome. Discussion To date, a comprehensive characterization of the dynamic landscape of lncRNAs during the NEtD process has not been performed. A temporal analysis of the PDX-based NEtD model has for the first time provided this dynamic landscape. TFBS analysis identified NEPC-related TF motifs present within the NEtD lncRNA sequences, suggesting functional roles for these lncRNAs in NEPC pathogenesis. Furthermore, select NEtD lncRNAs appear to be associated with metastasis and patients receiving ADT. Treatment-related metastasis is a clinical consequence of NEPC tumours. Top candidate lncRNAs FENDRR, H19, LINC00514, LINC00617, and SSTR5-AS1 identified in this study are implicated in the development of NEPC. We present here for the first time a genome-wide catalogue of NEtD lncRNAs that characterize the transdifferentiation process and a robust NEPC lncRNA patient expression signature. To accomplish this, we carried out the largest integrative study that applied a PDX NEtD model to clinical samples. These NEtD and NEPC lncRNAs are strong candidates for clinical biomarkers and therapeutic targets and warrant further investigation.
The breadth of the diaphragm: updates in embryogenesis and role of imaging
Koo, Chi Wan , Johnson, Tucker F. , Gierada, David S. , White, Darin , Matsumoto, Jane M., Levin, David L. , White, Darin B, Blackmon, Shanda, Choe, Jooae, Allen, Mark S. , Kuzo, Ronald S. , Blackmon, Shanda , Choe, Jooae

Mayo Clinic

The British Journal of Radiology | February 27, 2018 | Volume: No volume available | Issue: No issue available | Pages: 20170600

10.1259/bjr.20170600 | PMID 29485899 Get It

Quantitative assessment of lung stiffness in patients with interstitial lung disease using MR elastography
Marinelli, John P. , Levin, David L. , Hubmayr, Rolf D., McGee, Kiaran P. , Vassallo, Robert , Carter, Rickey E. , Ehman, Richard L.

Mayo Clinic

Journal of Magnetic Resonance Imaging | July 13, 2017 | Volume: 46 | Issue: 2 | Pages: No page available

10.1002/jmri.25805 Get It

PurposeTo investigate the use of magnetic resonance elastography (MRE) in the quantitative assessment of pulmonary fibrosis by comparing quantitative shear stiffness measurements of lung parenchyma in patients diagnosed with fibrotic interstitial lung disease (ILD) and healthy controls.Materials and MethodsA 1.5T spin‐echo, echo planar imaging MRE (SE‐EPI MRE) pulse sequence was utilized to assess absolute lung shear stiffness in 15 patients with diagnosed ILD and in 11 healthy controls. Data were collected at residual volume (RV) and total lung capacity (TLC). Spirometry data were obtained immediately prior to scanning. To test for statistical significance between RV and TLC shear stiffness estimates a two‐sample t‐test was performed. To assess variability within individual subject shear stiffness estimates, the intraclass correlation coefficient (ICC) and Krippendorff's alpha were calculated.ResultsPatients with ILD exhibited an average (±1 standard deviation) shear stiffness of 2.74 (±0.896) kPa at TLC and 1.32 (±0.300) kPa at RV. The corresponding values for healthy individuals were 1.33 (±0.195) kPa and 0.849 (±0.250) kPa, respectively. The difference in shear stiffness between RV and TLC was statistically significant (P < 0.001). At TLC, the ICC and alpha values were 0.909 and 0.887, respectively. At RV, the ICC and alpha values were 0.852 and 0.862, respectively.ConclusionIn subjects with known fibrotic interstitial lung disease, parenchymal shear stiffness is increased when compared to normal controls at both RV and TLC, with TLC demonstrating the most significant difference. MRE‐derived parenchymal shear stiffness is a promising new noninvasive imaging‐based biomarker of interstitial lung disease.Level of Evidence:1J. MAGN. RESON. IMAGING 2017;46:1–1
Differential Intraocular Pressure Measurements by Tonometry and Direct Cannulation After Treatment with Soluble Adenylyl Cyclase Inhibitors
Gandhi, Jarel K. , Chowdhury, Uttio Roy, Manzar, Zahid , Buck, Jochen , Fautsch, Michael P. , Marmorstein, Alan D. , Roy Chowdhury, Uttio, Levin, Lonny R. , Marmorstein, Alan D

Mayo Clinic

Journal of Ocular Pharmacology and Therapeutics | July 7, 2017 | Volume: 33 | Issue: 8 | Pages: 574-581

10.1089/jop.2017.0027 | PMID 28686538 Get It

Prospective study of proton‐beam radiation therapy for limited‐stage small cell lung cancer
Rwigema, Jean‐Claude M. , Lin, Liyong , Levin, William P., Evans, Tracey L. , Rengan, Ramesh , Langer, Corey J. , Cohen, Roger B. , Simone, Charles B. , Verma, Vivek , Berman, Abigail T. , Aggarwal, Charu , Simone, Charles B , Lin, Liyong

Mayo Clinic

Cancer | July 5, 2017 | Volume: 123 | Issue: 21 | Pages: 4244-4251

10.1002/cncr.30870 | PMID 28678434 Get It

BACKGROUNDExisting data supporting the use of proton‐beam therapy (PBT) for limited‐stage small cell lung cancer (LS‐SCLC) are limited to a single 6‐patient case series. This is the first prospective study to evaluate clinical outcomes and toxicities of PBT for LS‐SCLC.METHODSThis study prospectively analyzed patients with primary, nonrecurrent LS‐SCLC definitively treated with PBT and concurrent chemotherapy from 2011 to 2016. Clinical backup intensity‐modulated radiotherapy (IMRT) plans were generated for each patient and were compared with PBT plans. Outcome measures included local control (LC), recurrence‐free survival (RFS), and overall survival (OS) rates and toxicities.RESULTSThirty consecutive patients were enrolled and evaluated. The median dose was 63.9 cobalt gray equivalents (range, 45‐66.6 cobalt gray equivalents) in 33 to 37 fractions delivered daily (n = 18 [60.0%]) or twice daily (n = 12 [40.0%]). The concurrent chemotherapy was cisplatin/etoposide (n = 21 [70.0%]) or carboplatin/etoposide (n = 9 [30.0%]). In comparison with the backup IMRT plans, PBT allowed statistically significant reductions in the cord, heart, and lung mean doses and the volume receiving at least 5 Gy but not in the esophagus mean dose or the lung volume receiving at least 20 Gy. At a median follow‐up of 14 months, the 1‐/2‐year LC and RFS rates were 85%/69% and 63%/42%, respectively. The median OS was 28.2 months, and the 1‐/2‐year OS rates were 72%/58%. There was 1 case each (3.3%) of grade 3 or higher esophagitis, pneumonitis, anorexia, and pericardial effusion. Grade 2 pneumonitis and esophagitis were seen in 10.0% and 43.3% of patients, respectively.CONCLUSIONSIn the first prospective registry study and largest analysis to date of PBT for LS‐SCLC, PBT was found to be safe with a limited incidence of high‐grade toxicities. Cancer 2017;123:4244–4251. © 2017 American Cancer Society.
Evaluation of a projection-domain lung nodule insertion technique in thoracic computed tomography
Yu, Lifeng , Chen, Baiyu , Koo, Chi Wan , Takahashi, Edwin A. , Levin, David L. , Viers, Lyndsay D., Vincent-Sheldon, Stephanie, Ma, Chi , Kuzo, Ronald S. , Vincent-Sheldon, Stephanie A, Ma, Chi , Chen, Baiyu , Leng, Shuai , Leng, Shuai , Takahashi, Edwin A

Mayo Clinic

Journal of Medical Imaging | March 31, 2017 | Volume: 4 | Issue: 1 | Pages: 013510

10.1117/1.jmi.4.1.013510 | PMID 28401176 Get It

A virtual clinical trial using projection-based nodule insertion to determine radiologist reader performance in lung cancer screening CT
Yu, Lifeng , Hu, Qiyuan , Koo, Chi Wan , Takahashi, Edwin A. , Levin, David L. , Johnson, Tucker F. , Hora, Megan J., Dirks, Shane, Chen, Baiyu , McMillan, Kyle, Yu, Lifeng , Leng, Shuai , Fletcher, Joel G. , McCollough, Cynthia H. , Takahashi, Edwin A

Mayo Clinic

SPIE Proceedings | March 8, 2017 | Volume: 10132 | Issue: No issue available | Pages: 101321R

10.1117/12.2255593 | PMID 28392614 Get It

Chromosome 8 alterations and PTEN loss in Gleason grade 3 tumor to predict the presence of unsampled grade 4 tumor: Implications for active surveillance.
Jenkins, Robert B. , Said, Jonathan , Fine, Samson W. , Fedor, Helen, Gürel, Bora , Trock, Bruce J , Knudsen, Beatrice S. , Lotan, Tamara Levin , Marzo, Angelo M. De

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 32 | Issue: 4_suppl | Pages: 93-93

10.1200/jco.2014.32.4_suppl.93 Get It

93 Background: A key eligibility criterion in many active surveillance (AS) programs is that the biopsy exhibit only Gleason pattern 3 (G3) for a Gleason score of 6 or less. However, 25 to 35% of biopsy Gleason 6 is upgraded to Gleason 7 or higher in the prostatectomy (RP) specimen. Thus, there is a great need for biomarkers that, when measured on G3 tissue in a Gleason 6 biopsy, can predict the presence of unsampled higher grade tumor in the whole prostate. We evaluated PTEN loss by immunohistochemistry (IHC), and PTEN deletion, chromosome 8q (MYC) gain and 8p (LPL) loss by fluorescence in situ hybridization (FISH) for their ability to predict unsampled G4 tumor. Methods: A tissue microarray (TMA) was constructed of RP tissue from three groups of patients (n=50 per group) whose prostates exhibited only Gleason 3+3, only 3+4, or only 4+3 tumor, matched on age, year of RP, and race. In each patient, multiple cores sampled only from areas of G3 were evaluated for PTEN deletion by FISH, PTEN loss by IHC, and chromosome 8p/8q alterations by FISH. Biomarker results were compared between Gleason 6 versus 7 tumors using conditional logistic regression. Results: Patients underwent RP in 2001 to 2009, had median age 60, and median prostate-specific antigen 5.2; 63% of tumors were organ confined. In univariate analyses 8q gain (odds ratio OR=8.9, p<.0001), 8p loss (OR=6.9, p<.0001), PTEN loss by IHC (OR=5.7, p=.025), but not PTEN deletion by FISH (OR=1.5, p=.477) were significantly more common in G3 cores from Gleason 7 tumors than G3 cores from Gleason 6 tumors. In multivariable analyses, 8q gain (OR=6.2, p=.002) and 8p loss (OR=5.2, p=.0002) remained highly significant. At least one high risk biomarker (8q gain, 8p loss, PTEN loss, or PTEN deletion) was found in 35.7% of Gleason 3+3 versus 77.1% of Gleason 3+4 versus 91.3% of Gleason 4+3 tumors, p<.0001. Adjustment for confounding factors did not change the results. Conclusions: Chromosomal 8q gains (MYC), 8p loss (LPL), and PTEN loss measured in Gleason G3 TMA cores strongly differentiate whether the core comes from Gleason 6 or Gleason 7 tumor. If validated in biopsy Gleason 6 cores to predict prostatectomy Gleason 7 tumor these biomarkers could facilitate safe selection of men for active surveillance.